Related Experiment Video
Updated: Aug 29, 2025
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality
Frank Lezoualc'h1, Lina Badimon2, Hana Baker3
1Institut des Maladies Métaboliques et Cardiovasculaires, INSERM, Université Paul Sabatier, UMR 1297-I2MC, 1 avenue Jean Poulhès - BP 84225 - 31432 Toulouse Cedex 4, France.
Insights
Diabetic cardiomyopathy (CM) is a distinct heart condition. Current rodent models have limitations in mimicking human diabetic CM due to differences in environmental factors, disease control, and age, necessitating improved preclinical models.
Area of Science:
- Cardiology
- Endocrinology
- Molecular Biology
Background:
- Diabetic cardiomyopathy (CM) is a multifactorial heart disease characterized by ventricular hypertrophy and impaired contractility, independent of other cardiac conditions.
- Animal models are crucial for studying diabetic CM mechanisms but present limitations in human applicability.
- Key differences include environmental factors, duration of insulin resistance, diabetes control, and age discrepancies between animal models and human patients.
Approach:
- This review identifies limitations in current rodent models for diabetic cardiomyopathy.
- It discusses how future research should incorporate confounding factors to better replicate the human diabetic CM phenotype.
- The focus is on improving the translational relevance of preclinical studies.
Key Points:
- Rodent models often fail to replicate the duration of insulin resistance and environmental exposures crucial for human diabetic CM development.
- Studies in animal models frequently use uncontrolled diabetes, unlike the therapeutic interventions common in human patients.
- Age differences between young rodents and older human populations affected by type 2 diabetes mellitus pose a significant challenge.
Conclusions:
- Current rodent models have significant limitations in fully recapitulating the human diabetic cardiomyopathy phenotype.
- Future mechanistic and preclinical studies must integrate confounding factors like environmental exposures, diabetes control, and age to enhance translational validity.
- Improving animal models is essential for advancing our understanding and treatment of diabetic cardiomyopathy.
Abstract:
Diabetic cardiomyopathy (CM), occurring in the absence of hypertension, coronary artery disease, and valvular or congenital heart disease, is now recognized as a distinct, multifactorial disease leading to ventricular hypertrophy and abnormal myocardial contractility that correlates with an array of complex molecular and cellular changes. Animal models provide the unique opportunity to investigate mechanistic aspects of diabetic CM, but important caveats exist when extrapolating findings obtained from preclinical models of diabetes to humans. Indeed, animal models do not recapitulate the complexity of environmental factors, most notably the duration of the exposure to insulin resistance that may play a crucial role in the development of diabetic CM. Moreover, most preclinical studies are performed in animals with uncontrolled or poorly controlled diabetes, whereas patients tend to undergo therapeutic intervention. Finally, whilst type 2 diabetes mellitus prevalence trajectory mainly increases at 40- < 75 years (with a currently alarming increase at younger ages, however), it is a legitimate concern how closely rodent models employing young animals recapitulate the disease developing in old people. The aim of this review is to identify the current limitations of rodent models and to discuss how future mechanistic and preclinical studies should integrate key confounding factors to better mimic the diabetic CM phenotype.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care